₹271.15▲3.63%
3.32%
Low
Day's Volatility:3.82%
High
0.50%
19.79%
Low
52 Weeks Volatility:33.04%
High
13.26%
Returns % | |
1 Month Return | 3.75 % |
3 Month Return | -0.32 % |
1 Year Return | 15.95 % |
Market Stats | |
Previous Close | ₹261.65 |
Open | ₹264.40 |
Volume | 86.01L |
Upper Circuit | - |
Lower Circuit | - |
Market Cap | ₹31,413.70Cr |
based on 19 analysts
Based on 19 analysts offering long term price targets for Biocon Ltd. An average target of ₹279.11
Source: S&P Global Market Intelligence
Organisation | Biocon Ltd |
Headquarters | Bangalore |
Industry | Pharmaceuticals |
E-voting on shares | Click here to vote |
Key events for Biocon Ltd
Biocon has received approval from the South African Health Products Regulatory Authority for their drug product Tacrolimus capsule used in organ transplant patients. Additionally, Biocon reported a consolidated net profit of Rs 660 crore in Q3 FY24 with a YoY revenue jump of 34.43%.
Biocon Receives Approval for Tacrolimus Capsule in South Africa - 20 Apr, 2024
Biocon has received approval from the South African Health Products Regulatory Authority (SAHPRA) for their drug product Tacrolimus capsule, used to treat organ transplant patients. The company reported a consolidated net profit of Rs 660 crore in Q3 FY24 and revenue from operations jumped 34.43% YoY to Rs 3,953.7 crore. However, the stock fell by 2.10% on Friday, April 19, 2024.
Biocon Signs Licensing Agreement with Biomm for Commercialisation of Semaglutide in Brazil - 18 Apr, 2024
Biocon has signed a licensing and supply agreement with Biomm SA for the commercialisation of its diabetes drug Semaglutide (gOzempic) in Brazil. Biocon will undertake development, manufacturing and supply of the drug product, while Biomm will be responsible for obtaining regulatory approval and commercialisation in the Brazilian market. The potential market for Semaglutide in Brazil stands at around $580 million.
Biocon Partners with Biomm SA for Diabetes Drug Commercialisation in Brazil - 17 Apr, 2024
Biocon has partnered with Biomm SA for the commercialisation of its diabetes drug Semaglutide (gOzempic) in Brazil. Meanwhile, ICICI Securities expects Biocon's Q4 net profit to be at Rs 67.1 crore, down 192.8% YoY.
Biocon Pivots to Anti-Obesity Therapies Amid Patent Expirations - 08 Apr, 2024
Biocon Ltd is leading Indian drugmakers in the race to grab a slice of the $100 billion obesity drugs market, as patents for blockbuster medications start to expire. Biocon has scored an early win among its peers with UK approval for the first generic version of liraglutide injectable.
Biocon Transfers Branded Formulations Business to Eris Lifesciences - 03 Apr, 2024
Biocon Biologics has completed the transfer of its branded formulations business in India to Eris Lifesciences for Rs 1,242 crore. The transaction was conducted on a slump sale basis and includes metabolics, oncology, and critical care diagnostics.
Biocon Receives Approval for gSaxenda Formulation - 01 Apr, 2024
Biocon's complex formulation Liraglutide (gSaxenda) has received approval from MHRA, UK, leading to a 1.7% rise in the company's stock. The pharmaceuticals and drugs sector saw investments exceeding expectations, with Biocon being one of the major beneficiaries. In Q3 FY24, Biocon reported a consolidated net profit of Rs 660 crore.
Biocon Receives Approval for Diabetes Drug Liraglutide in UK - 28 Mar, 2024
Biocon Ltd has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), UK, for its complex formulation Liraglutide used in treating Type-2 Diabetes Mellitus. The approval is an important milestone as it strengthens Biocon's leadership in delivering many firsts on complex drug products. Shares rose by over 3%. Biocon's operating revenues and profit figures have shown a stellar performance during recent financial quarters.
Biocon Stock Rises as Bernstein Maintains Ratings - 27 Mar, 2024
Biocon Ltd's stock rises for the fifth consecutive day, while foreign brokerage firm Bernstein maintains its outperform and underperform ratings on major pharmaceutical companies.
Fundamentals of Biocon Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Retail Holding Up
Retail Investor have increased holdings from 17.96% to 19.73% in Mar 2024 quarter
Revenue Rich
Revenue is up for the last 3 quarters, 3.51K Cr → 4.54K Cr (in ₹), with an average increase of 11.6% per quarter
Profit Spike
Netprofit is up for the last 3 quarters, 101.4 Cr → 660.0 Cr (in ₹), with an average increase of 50.1% per quarter
Against Peers
In the last 3 years, Shree Ganesh Remedies Ltd has given 151.3% return, outperforming this stock by 185.8%
Promoter Holding Unchanged
Promoters holdings remained unchanged at 60.64% of holdings in Mar 2024 quarter
Against Peers
In the last 1 year, Shree Ganesh Remedies Ltd has given 99.0% return, outperforming this stock by 83.0%
Price Dip
In the last 3 years, BIOCON stock has moved down by -34.5%
MF Holding Down
Mutual Funds have decreased holdings from 9.31% to 8.57% in Mar 2024 quarter
FII Holding Down
Foreign Institutions have decreased holdings from 6.55% to 5.63% in Mar 2024 quarter
Biocon Ltd in the last 5 years
Lowest (24.48x)
March 19, 2024
Today (26.06x)
April 19, 2024
Industry (61.04x)
April 19, 2024
Highest (118.86x)
September 27, 2018
Funds | Holdings |
SBI Contra Fund Direct Growth | 1.65% |
Mirae Asset Large Cap Fund Direct Plan Growth | 0.73% |
SBI Balanced Advantage Fund Direct Growth | 0.92% |
Quant Flexi Cap Fund Growth Option Direct Plan | 3.21% |
Quant Mid Cap Fund Growth Option Direct Plan | 2.29% |
Investors | Holdings % | Prev. 1 periods | 3M change |
---|---|---|---|
Promoter Holdings | 60.64% | 0.00 | |
Foreign Institutions | 5.63% | 0.00 | |
Mutual Funds | 8.57% | 0.00 | |
Retail Investors | 19.73% | 0.00 | |
Others | 5.43% | 0.00 |
Technicals of Biocon Ltd share
News & Events of Biocon Ltd
Biocon Ltd (BIOCON) share price today is ₹271.15
Biocon Ltd is listed on NSE
Biocon Ltd is listed on BSE
PE Ratio of Biocon Ltd is 26.06
PE ratio = Biocon Ltd Market price per share / Biocon Ltd Earnings per share
Today’s traded volume of Biocon Ltd(BIOCON) is 86.01L.
Today’s market capitalisation of Biocon Ltd(BIOCON) is ₹31413.7Cr.
Biocon Ltd(BIOCON | Price |
---|---|
52 Week High | ₹307.1 |
52 Week Low | ₹217.5 |
Biocon Ltd(BIOCON) share price is ₹271.15. It is down -11.71% from its 52 Week High price of ₹307.1
Biocon Ltd(BIOCON) share price is ₹271.15. It is up 24.67% from its 52 Week Low price of ₹217.5
Biocon Ltd(BIOCON | Returns |
---|---|
1 Day Returns | 9.5% |
1 Month Returns | 3.75% |
3 Month Returns | -0.32% |
1 Year Returns | 15.95% |